Spermine Oxidase Activity in Breast Cancer and Anticancer Effects of Spermine Analogues
Author Information
Author(s): Cervelli Manuela, Bellavia Gabriella, Fratini Emiliano, Amendola Roberto, Polticelli Fabio, Barba Marco, Federico Rodolfo, Signore Fabrizio, Gucciardo Giacomo, Grillo Rosalba, Woster Patrick M, Casero Robert A Jr, Mariottini Paolo
Primary Institution: Dipartimento di Biologia, Università Roma Tre, Rome, Italy
Hypothesis
This study investigates the expression of spermine oxidase (SMO) and its prognostic significance in breast cancer.
Conclusion
The underexpression of SMO is a negative marker in breast cancer, and the spermine analogues BENSpm and CPENSpm are effective SMO inhibitors.
Supporting Evidence
- SMO mRNA and enzyme activity were significantly lower in breast cancer samples compared to non-tumor samples.
- Both spermine analogues BENSpm and CPENSpm were found to be good inhibitors of SMO activity.
- The study suggests that low SMO activity may contribute to tumor growth by decreasing local H2O2 concentrations.
Takeaway
This study found that a protein called spermine oxidase is less active in breast cancer tissues, which might help tumors grow. Two drugs that affect this protein were tested and found to be good at stopping its activity.
Methodology
Breast cancer tissue samples were analyzed for SMO transcript levels and enzyme activity, and biochemical analyses of spermine analogues were conducted in vitro.
Limitations
The study is limited to a small sample size and may not represent all breast cancer cases.
Participant Demographics
The study included 20 patients with a mean age of 72.9 years, primarily women over 50.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website